肿瘤细胞治疗研究
FRONTIER PAPERS
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy.
我们提供了首个用于ESCC精准化疗免疫治疗的代谢组学路线图，将基线预测、纵向监测和饮食调节统一为一个临床可操作的范式。
Metformin sensitizes esophageal squamous cell carcinoma to Vγ9Vδ2 T cell-mediated cytotoxicity by upregulating BTN3A1 and BTN2A1.
二甲双胍是一种一线抗糖尿病药物，具有广谱抗肿瘤特性，但其潜在的免疫调节机制尚未完全阐明。
Heterozygous germline deletion in Hif3a exacerbates esophageal squamous cell carcinoma development.
种系变异与食管鳞状细胞癌（ESCC）的易感性有关。
Integrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewi
NMB是ESCC转移适应的关键驱动因素，通过基因组进化和免疫重塑在转移定植过程中赋予肿瘤细胞生存优势，代谢适应是基因组改变的下游结果。
Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy.
CAR-T 细胞疗法在血液系统恶性肿瘤中展现出显著疗效，但在实体瘤中仍受限于肿瘤渗透不足、免疫抑制微环境及细胞因子释放综合征（CRS）风险。
PVR Mediates Resistance to IL21.CD276.CAR-T Therapy in Esophageal Squamous Cell Carcinoma.
嵌合抗原受体（CAR）-T疗法在实体瘤中已取得部分疗效，但其整体有效性仍然有限。
Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.
iPSC来源的MUC1靶向CAR-NK细胞对人ESCC发挥强效且特异性的抗肿瘤作用，支持这种现货型细胞疗法的临床转化。
Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.
我们的研究结果表明，多西他赛通过调节细胞焦亡通路增强前列腺癌的免疫治疗疗效。这种方法可能为临床管理提供一种新的治疗策略。
Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response.
我们的发现提供了ESCC的全面免疫景观，突出了关键的免疫缺陷和靶向干预的机会。
Efficacy and safety of thymosin combined with anticancer therapy for esophageal cancer: a systematic review and meta-analysis of randomized controlled
现有证据提示，胸腺素联合抗肿瘤治疗用于食管癌可能增强抗肿瘤疗效、改善患者免疫功能，并减少传统治疗相关的毒性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
